⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCAB News
BioAtla, Inc. Common Stock
Form 8-K
sec.gov
CNTX
BCAB
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
globenewswire.com
CNTX
BCAB
Form 8-K
sec.gov
BCAB
BioAtla Announces Share Consolidation
globenewswire.com
BCAB
Form 8-K
sec.gov
BCAB
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com
BCAB
Form 8-K
sec.gov
BCAB
Form 8-K
sec.gov
BCAB
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
globenewswire.com
BCAB
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
globenewswire.com
BCAB